This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Rossari Biotech Q2 revenue up 19% YoY, H1 revenue up 23%, PAT up 5%
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Rossari Biotech reported Q2 FY26 consolidated revenue of Rs 697.56 cr, up 19% YoY from Rs 586.11 cr. H1 FY26 revenue rose 23% to Rs 1,394.76 cr vs Rs 1,129.82 cr. Q2 consolidated PAT grew 5.5% to Rs 38.91 cr; H1 PAT up 5% to Rs 74 cr. Standalone Q2 revenue up 18% to Rs 495.28 cr; H1 standalone PAT Rs 68.50 cr, up 19%. H1 operating cashflow strong at Rs 131.42 cr vs negative Rs 25 cr prior year. Limited review by Walker Chandiok was clean. Board also approved land lease for a new greenfield manufacturing plant in Saudi Arabia via subsidiary. No exceptional items reported.
Steady revenue growth, modest profit gains; new Saudi plant signals expansion. Margins slightly under pressure.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹697.6 Cr | ₹586.1 Cr | +19.0% |
| Operating profit | ₹48.20 Cr | ₹47.60 Cr | +1.3% |
| Profit after tax | ₹38.91 Cr | ₹36.88 Cr | +5.5% |
| EBITDA margin | 12.5% | 12.3% | +0.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.